PulseAugur
实时 05:54:13
中文(ZH) 圣晖集成:控股子公司中标约2.23亿元项目

Shenghui Integration subsidiary wins $22.3M Indonesian construction project

Shenghui Integration's Indonesian subsidiary has secured a significant construction project valued at approximately 223 million RMB. This project involves the development of a shoe sole and footwear production facility. Separately, a subsidiary of Sunshine Nuohe has received approval for clinical trials for its STC009 injection, intended for treating secondary hyperparathyroidism. AI

影响 This cluster reports on a construction project win and a drug trial approval, with no direct impact on AI operators.

排序理由 The cluster contains news about subsidiaries winning contracts and receiving regulatory approval for drug trials, which are not frontier AI releases or significant industry-wide events.

在 36氪 (36Kr) 阅读 →

AI 生成摘要 · Google Gemini · 来自 1 个来源。 我们如何撰写摘要 →

报道来源 [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Shenghui Integration: Subsidiary Wins Bid for Project Worth Approximately 223 Million Yuan

    36氪获悉,圣晖集成公告,公司控股子公司PT ACTER INTEGRATION TECHNOLOGY INDONESIA(简称“印尼合资公司”)于近日收到PT. Hardases Abadi Indonesia发来的通知,印尼合资公司中标“PT.HAI F12及F12-1胶底与鞋类生产厂房第二期建设案”,工程总价为5628亿印尼卢比(未税),约为人民币2.23亿元(未税)。